Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
The Role and Mechanism of P2X7 Receptor in Cancer and...
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

The Role and Mechanism of P2X7 Receptor in Cancer and Inflammatory Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: 30 July 2024 | Viewed by 887

Special Issue Editor

Dr. Anna Lisa Giuliani

E-Mail Website
Guest Editor
Department of Medical Sciences, University of Ferrara, Via Borsari 46, 44121 Ferrara, Italy
Interests: cancer research; cell culture; immunology; molecular biology; cancer biology; signaling pathways; cell biology; antibodies; inflammation; flow cytometry

Special Issue Information

Dear Colleagues,

The purpose of this Special Issue is to summarize the roles and mechanisms of P2X7 receptors in human diseases, particularly in cancer and inflammatory diseases. The P2X7 receptor is an ATP-gated non-selective cation channel that is widely expressed in a variety of immune and nonimmune cells. P2X7 receptors play a key role in inflammation and immunomodulation, such as signal transduction and the activation of immune cells. The activity of P2X7 receptors in tumour growth and dissemination is also of interest. The awareness about the role of P2X7 in human diseases and the consideration of the P2X7 receptor as a potential target for the treatment of inflammatory diseases and cancer are constantly increasing.

This Special Issue aims to publish high-quality manuscripts that provide insights into the molecular mechanisms of P2X7 receptors in cancer and inflammatory diseases.

Dr. Anna Lisa Giuliani
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • P2X7 receptor
  • inflammation
  • cancer
  • purinergic signalling

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 2828 KiB  
Article
Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice
by Peter Cuthbertson, Amy Button, Chloe Sligar, Amal Elhage, Kara L. Vine, Debbie Watson and Ronald Sluyter
Int. J. Mol. Sci. 2024, 25(3), 1775; https://doi.org/10.3390/ijms25031775 - 01 Feb 2024
Viewed by 753
Abstract
Allogeneic haematopoietic stem cell transplantation (HSCT) leads to the establishment of graft-versus-leukaemia (GVL) immunity, but in many cases also results in the development of graft-versus-host disease (GVHD). This study aimed to determine if P2X7 antagonism using Brilliant Blue G (BBG) could improve the [...] Read more.
Allogeneic haematopoietic stem cell transplantation (HSCT) leads to the establishment of graft-versus-leukaemia (GVL) immunity, but in many cases also results in the development of graft-versus-host disease (GVHD). This study aimed to determine if P2X7 antagonism using Brilliant Blue G (BBG) could improve the beneficial effects of post-transplant cyclophosphamide (PTCy) in a humanised mouse model of GVHD, without comprising GVL immunity. NOD.Cg-Prkdcscid Il2rgtm1Wjl (NSG) mice were injected with human peripheral blood mononuclear cells (PBMCs) (Day 0), then with cyclophosphamide (33 mg/kg) on Days 3 and 4, and with BBG (50 mg/kg) (or saline) on Days 0–10. PTCy with BBG reduced clinical GVHD development like that of PTCy alone. However, histological analysis revealed that the combined treatment reduced liver GVHD to a greater extent than PTCy alone. Flow cytometric analyses revealed that this reduction in liver GVHD by PTCy with BBG corresponded to an increase in human splenic CD39+ Tregs and a decrease in human serum interferon-γ concentrations. In additional experiments, humanised NSG mice, following combined treatment, were injected with human THP-1 acute myeloid leukaemia cells on Day 14. Flow cytometric analyses of liver CD33+ THP-1 cells showed that PTCy with BBG did not mitigate GVL immunity. In summary, PTCy combined with BBG can reduce GVHD without compromising GVL immunity. Future studies investigating P2X7 antagonism in combination with PTCy may lead to the development of novel treatments that more effectively reduce GVHD in allogeneic HSCT patients without promoting leukaemia relapse. Full article
(This article belongs to the Special Issue The Role and Mechanism of P2X7 Receptor in Cancer and Inflammatory Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop